Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells

Journal of Experimental & Clinical Cancer Research

Kazunari K. Yokoyama¹  Kenly Wuputra¹  Chia-Chen Ku¹  Deng-Chyang Wu²  Ying-Chu Lin³  Shigeo Saito⁴ 

[1] Graduate Institute of Medicine, Kaohsiung Medical University;Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University Hospital;School of Dentistry, School of Medicine, Kaohsiung Medical University;Waseda University Research Institute for Science and Engineering;

关键词: Cancer risk;    Cell reprogramming;    Pluripotent stem cells;    Regenerative medicine;    Therapeutic agents;   

DOI  :  10.1186/s13046-020-01584-0

来源: DOAJ

【 摘 要 】

Abstract Human pluripotent embryonic stem cells have two special features: self-renewal and pluripotency. It is important to understand the properties of pluripotent stem cells and reprogrammed stem cells. One of the major problems is the risk of reprogrammed stem cells developing into tumors. To understand the process of differentiation through which stem cells develop into cancer cells, investigators have attempted to identify the key factors that generate tumors in humans. The most effective method for the prevention of tumorigenesis is the exclusion of cancer cells during cell reprogramming. The risk of cancer formation is dependent on mutations of oncogenes and tumor suppressor genes during the conversion of stem cells to cancer cells and on the environmental effects of pluripotent stem cells. Dissecting the processes of epigenetic regulation and chromatin regulation may be helpful for achieving correct cell reprogramming without inducing tumor formation and for developing new drugs for cancer treatment. This review focuses on the risk of tumor formation by human pluripotent stem cells, and on the possible treatment options if it occurs. Potential new techniques that target epigenetic processes and chromatin regulation provide opportunities for human cancer modeling and clinical applications of regenerative medicine.

【 授权许可】

Unknown